Cagrilintide mastery course
Unit 2 of 11

The amylin hormone

Every time your pancreas releases insulin after a meal, it releases a second hormone alongside it: amylin.

The forgotten twin of insulin

Every time your pancreas releases insulin after a meal, it releases a second hormone alongside it: amylin. For decades amylin was overshadowed by insulin, but it turns out to be a key brake on appetite and a regulator of how fast food leaves the stomach.

This unit covers the biology cagrilintide is built on: what amylin does, the unusual receptor it uses, and the "amyloid" problem that made copying it surprisingly hard.

Key terms

Released with insulin

Amylin is co-secreted with insulin from pancreatic beta cells after a meal, as a small, fairly fixed fraction of the insulin: one review puts it at about 1 part amylin to 100 parts insulin, another at about 2 to 5%. While insulin tells the body's tissues to take up and store nutrients, amylin sends a parallel message to the brain, acting mainly on the caudal hindbrain, the lowest part of the brainstem: the meal is arriving, start feeling full. The two hormones are partners, released together and acting on different targets.

Insulin and amylin, a hormonal pair

This pairing explains why amylin became an obesity target. It is a built-in, meal-triggered appetite brake that the body already uses. A drug that safely amplifies amylin is not introducing a foreign mechanism; it is turning up a natural post-meal signal that helps end eating, which is exactly what cagrilintide is designed to do.

AdvancedWhy amylin was overlooked for so long

Amylin was identified in 1986, when two independent groups found it as the major component of the pancreatic islet amyloid deposits long known as a hallmark of type 2 diabetes, so it was first known through a disease rather than through its normal physiology. It was identified as a circulating hormone in 1989. Its first use as a drug target was glucose control: with type 1 and late-stage type 2 diabetes seen as amylin-deficient conditions, amylin replacement became the goal, and the meal-ending satiation role that cagrilintide builds on was worked out in the research that followed.


What amylin does


An unusual receptor


The amyloid problem


Why amylin became an obesity target